Annual report pursuant to Section 13 and 15(d)

Acquisition of patents

v2.4.0.8
Acquisition of patents
 12 Months Ended
May 31, 2014
Acquisition of patents

Note 12 – Acquisition of patents

As discussed in Note 11 above, the Company consummated an asset purchase on October 16, 2012 and paid $3,500,000 for certain assets, including intellectual property, certain related licenses and sublicenses, FDA filings and various forms of the PRO 140 drug product. The Company followed the guidance in Financial Accounting Standards topic 805 to determine if the Company acquired a business. Based on the prescribed accounting, the Company acquired assets and not a business. As of May 31, 2014, the Company has recorded $3,500,000 of intangible assets in the form of patents. The Company estimates the patents have an estimated life of ten years.

As of the date of this filing, management cannot reasonably estimate the likelihood of paying the milestone payments and royalties described in Note 11 and, accordingly, as of May 31, 2014, the Company has not accrued any liabilities related to these contingent payments, as more fully described above in Note 11.

The following presents intangible assets activity:

 

     May 31, 2014     May 31, 2013  

Gross carrying amounts

    $ 3,500,000      $ 3,500,000   

Accumulated amortization

      (568,750 )      (218,750 ) 
  

 

 

    

 

 

  

Total amortizable intangible assets, net

      2,931,250        3,281,250   

Patents currently not amortized

      35,989        35,989   
  

 

 

    

 

 

  

Carrying value of intangibles, net

    $ 2,967,239      $ 3,317,239   
  

 

 

    

 

 

  

Amortization expense related to intangible patents was approximately $350,000 and $219,000 for the year ended May 31, 2014 and May 31, 2013, respectively. The estimated aggregate future amortization expense related to the Company’s intangible assets with finite lives is estimated at approximately $350,000 per year for the next five years.